key: cord-0740463-mt61b7o7 authors: Li, Kezhen; Chen, Ge; Hou, Hongyan; Liao, Qiuyue; Chen, Jing; Bai, Hualin; Lee, Shiyeow; Wang, Cheng; Li, Huijun; Cheng, Liming; Ai, Jihui title: Analysis of sex hormone, menstruation and ovarian reserve in COVID-19 women of child-bearing age: a cross-sectional study date: 2020-09-29 journal: Reprod Biomed Online DOI: 10.1016/j.rbmo.2020.09.020 sha: 6ab2d1562f19ffa18f460a83b42b08a096dfd8fa doc_id: 740463 cord_uid: mt61b7o7 RESEARCH QUESTION: Whether SARS-CoV-2 infection has effects on ovarian reserve, sex hormone and menstruation of women of child-bearing age. DESIGN: This is a retrospective, cross-sectional study. Clinical and laboratory data from 237 women of child-bearing age diagnosed with COVID-19 were retrospectively reviewed. Menstrual data from 177 patients were analyzed. Blood samples from the early follicular phase were tested for sex hormones and Anti-mullerian hormone (AMH). RESULTS: Among 237 patients confirmed with COVID-19, severely ill patients had more comorbidities than mildly ill patients (34% vs 8%), especially for patients with diabetes, hepatic disease and malignant tumors. Among 177 patients with menstrual records, 45 (25%) patients presented with menstrual volume changes, and 50 (28%) patients had menstrual cycle changes, mainly a decreased volume (21%) and a prolonged cycle (19%). The average sex hormone and AMH levels of women of child-bearing age with COVID-19 were not different from those of age-matched controls. CONCLUSIONS; Average sex hormone levels and ovarian reserve did not change significantly in COVID-19 women of child-bearing age. Nearly one-fifth of patients exhibited a menstrual volume decrease or cycle prolongation. The menstruation changes of these patients might be the consequence of transient sex hormone change cause by suppression of ovarian function that soon resumed after recovery. In December 2019, an outbreak of the novel coronavirus disease 2019 occurred in Wuhan, China. Currently, COVID-19 has been spreading around the world rapidly and has become a major disaster affecting public health. Through June 14, 2020, a total of 7,865,794 people has been diagnosed with COVID-19 globally, with a cumulative death toll of 432,394 (https://www.worldometers.info/coronavirus/). Recently, many studies have reported the general epidemiology, clinical, and laboratory characteristics of patients with COVID-19 . Numerous retrospective studies have predicted that age is a crucial factor related to the prognosis of COVID-19 patients (Guan, et al., 2020) . In addition, sex is considered to play an important role in COVID-19 progression since a better prognosis is observed in female patients . Similarly, some infectious diseases such as MERS and SARS have mild clinical symptoms and better outcomes in women of childbearing age (Alghamdi, et al., 2014 , Karlberg, et al., 2004 . Does COVID-19 show the same characteristics? COVID-19 patients have been reported to have multisystem complications in addition to respiratory symptoms, such as issues with the cardiovascular and digestive systems , Guan, 2020 , Guan, et al., 2020 . One possible mechanism might be that the pathogen that causes COVID-19, severe acute respiratory syndrome coronavirus (SARS-CoV-2), enters cells through its receptor, angiotensin converting enzyme 2 (ACE2) (Hoffmann, et al., 2020) . Organs with high expression of ACE2 might therefore be attacked by this virus . ACE2 has been reported to be highly expressed in adult male Leydig cells of the testis (Douglas, et al., 2004) , and male COVID-19 patients have been reported to have abnormal sex hormone levels compared with healthy men, suggesting that male reproductive endocrine function might be injured by viral infection . In a previous animal study, ACE2 expression has also been reported on ovarian granulosa cells (Honorato-Sampaio, et al., 2012) , which means the ovary might also become the target of SARS-CoV-2. In addition, one study reported that the cellular immune response plays a significant role during HBV and HCV infections, which may result in abnormal ovarian function (Kurmanova, 2016) . In addition, the treatment process affects the female hypothalamic-gonadal-axis (Kao, et al., 2019) .The glucocorticoids treatments might be used in some cases, and their effect on the reproductive and endocrine system in women of child-bearing age is not yet known. Currently, there are no clinical data on the impact of COVID-19 on the ovarian function of women of child-bearing age. Over the last decade, female reproductive health has been seen to be of increasing importance, and attention to the effects of COVID-19 on the reproductive system has been called for globally. Therefore, clinical evidence to confirm whether COVID-19 viral infection causes endocrine disorders and ovary damage in women of child-bearing age is urgently needed. This study aimed to systematically report and analyze the epidemiological, clinical and laboratory characteristics of female COVID-19 patients of child-bearing age and to identify any effects the viral infection has on ovarian function. A retrospective analysis of the clinical data and menstrual changes of inpatient women of child-bearing age and the serum sex hormone indexes of patients in the early follicular phase was conducted. We performed a single-center, retrospective study of all women of child-bearing age with confirmed COVID-19 who were hospitalized in Tongji Hospital from January 19 to April 1, 2020. Inclusion criteria: women between 18-45 years old. Exclusion criteria: 1. Pregnant or lactating. 2. History of a diagnosis of ovarian dysfunction in latest six months before disease: a manifestation of delayed menses, menstrual irregularities, or earlier menopause 3. Prior hysterectomy or oophorectomy. Eventually, 237patients were enrolled, 177 of them with a complete menstrual history, and 91 of the latter had serum specimens in the early follicular phase. From June 2019 to March 2020, nonovarian infertility patients who received fertility testing in the early follicular phase were selected as control. All of the inclusion and exclusion criteria were the same as the COVID-19 group. After screening and verification, they were randomly 1:1 matched with the patient group by age. Tongji Hospital has established a database (Yiduyun Technology, Beijing, China) of medical records and blood specimens for all inpatients. Demographic characteristics, age, menstrual history, comorbidities, signs, symptoms at the onset of diseases, laboratory and radiological examination results, progression, prognosis, and treatment were retrieved from the database. The menstrual information of the patients after discharge was collected by phone follow-up until May 23, 2020. Through the comparison of menstrual histories, 91 serum samples in any one day of the first 4 days of the menstrual cyclewere kept in the specimen bank and were used to test for sex hormones and AMH. The blood sample were taken at any day of first 5 day in the menstrual cycle during the disease when patients were still hospitalized. For patients who experienced two or more than two menstrual cycles during their hospitalization, we used the blood sample taken in the first cycle after symptoms onset. A total of 91 control patients were identified, and their sex hormone test results were extracted from their electronic medical records. This study was approved by The Institutional Review Board of Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology (TJ-IRB20200368). Informed consent was exempted in accordance with the urgent situation and the Ethics Committee's rules. Serum testosterone (T), estradiol (E2), progesterone (P), luteinizing hormone (LH), follicle stimulating hormone (FSH), anti-mullerian hormone (AMH) were detected by electro chemiluminescent immunoassays according to the instructions from the manufacturer (BeckmanCoulter, US and cobas e411, Roche, Switzerland). All of the enrolled patients were confirmed to have COVID-19 according to the New Coronavirus Pneumonia Prevention and Control Program (5th edition). In brief, a case should be diagnosed as COVID-19 with a positive RT-PCR result of SARS-CoV-2, or typical computerized tomography (CT) evidence of viral pneumonia. Patients were defined as mild or severe as follows: (1) mild: mild clinical symptoms with or without typical CT imaging of viral pneumonia; (2) severe: oxygen saturation ≤95% at rest, or respiratory distress with RR < 30 times/min, or arterial partial oxygen pressure (PaO 2 )/oxygen absorption concentration (FiO2) ≤300 mmHg, or respiratory failure that requires mechanical ventilation, or shock, or organ failure that needs intensive care. Abnormal hepatic function was defined as alanine aminotransferase >66 U/L. Abnormal renal function was defined as blood creatinine >84 µmol/L, or the concentration of blood urea nitrogen >7.5 mmol/L. Heart function injury was defined as hypersensitive cardiac troponin >15.6 pg/mL or N-terminal pro-brain natriuretic peptide >116 pg/mL. Digestive system injury was defined as developing severe symptoms of the digestive tract, such as nausea, vomiting, abdominal pain and diarrhea. Respiratory system injury was defined as hypoxia symptoms that required oxygen administration. Nervous system injury was defined as the appearance of seizures, coma or drowsiness. The prolonged or shortened menstrual cycle was defined as a prolongation or shortening more than 7 days comparing with the average of the latest six-months cycles of the same patient before the disease. The decreased or increased menstrual volume was compared with the previous menstrual volume of the same patient before the disease. A menstrual disorder was defined as patients with both prolonged and shortened menstrual cycles for three months. All of the statistical analyses were performed using SPSS version 26.0 (IBM). Age-matched controls were randomly selected by case-control matching. T-tests were used for two-group comparisons. Continuous variables were described as the meanstandard deviation (SD) when normally distributed or median (interquartile range, IQR) when not, and categorical variables were described as number (percentage). Univariable logistic regression models were conducted to analyze the risk factors. A value of P<0.05 was considered statistically significant. We included a total of 237 patients with confirmed COVID-19 in this study. The median age of the patients was 37 years, and their clinical characteristics are shown in Table 1 . In total, there were 147 (62%) patients in the mild group and 90 (38%) patients in the severe group. Overall, the presence of comorbidities was more common in severely ill patients (31 (34%)) than they were in mildly ill patients (12 (8%)), especially those with diabetes, hepatic disease and malignant tumors. Onset symptoms showed no differences between the two groups except that chest tightness was more common in the mild group. Among all of the patients, respiratory, digestive and cardiac complications were the ones most commonly seen. Nervous system complications only appeared in severe patients. There were no differences in complications between mild and severe patients. The laboratory characteristics of COVID-19 are shown in Table S1 . In severe patients, PCT, Bun, D-Dimer, 8 interleukin (IL)-6, interleukin (IL)-8, interleukin (IL)-10and interleukin (IL)-2R levels were significantly higher than in mild patients. However, there were no significant differences in routine blood and biochemistry examinations, coagulation function, immune-related indicators, other infection-related indicators or cytokines between the two groups. A total of 177 patients were included in the menstrual analysis because they had complete menstrual history records in the database. For those with the disease, 136 (75%) patients had no change of menstrual volume, 36 (20%) patients had a significant decrease in menstrual volume, and only 9 (5%) patients had an increased volume ( Figure 1A ). The distribution of menstrual volume in the mild and severe patients shown in Figures 1B and 1C . We found 88 (74%) mildly ill patients had no change in menstrual volume, while 24 (20%) had decreased and 7 (6%) had increased volumes. In severely ill patients, 44 (76%) had no change in menstrual volume, 12 (21%) had decreased and 2 (3%) had increased volumes. The distribution was consistent with the general population. Further statistical analysis showed no significant differences between mild patients and severe patients in menstrual volume changes ( Figure 1D -E). The menstrual cycle distribution of 177 patients is shown in Figure 2A . There were 25 (14%) patients with a menstrual cycle less than 28 days, 66 (37%) between 28 days to 32 days, 31 (18%) between 33 to 37 days, 43 (24%) patients had cycles longer than 37 days, and 12 (7%) patients showed a cycle disorder. The distribution of menstrual cycles in mild and severely ill patients is shown in Figures 2B and 2C . Both groups had 6 patients with menstrual disorders. Cycles less than 28 days affected 18 (15%) mildly ill patients and 7 (12%) severe patients. Cycles between 28 days to 32 days were seen in 47 (40%) mildly ill patients and 19 (33%) severely ill patients. Cycles between 33 days to 37 days were experienced by 25 (21%) mild and 6 (10%) severely ill patients, respectively, while 23 (19%) mildly ill patients had cycles longer than 37 days, while 20 (34%) severely ill patients had cycles longer than 37 days, a further statistical analysis showed a significant difference ( Figure 2D ). For the individual differences in a normal menstrual cycle, we further analyzed the menstrual cycle changes during disease compared with the patients' regular cycles. We found 127 (72%) patients had no change in their menstrual cycle, 33 (19%) patients had prolonged cycles, 5 (3%) patients had shorten cycles and 12 (6%) showed cycle disorders ( Figure 3A ). The distribution of the menstrual cycle changes in the mildly and severely ill patients are shown in Figures 3B and 3C. We found 88 (74%) mildly ill patients and 39 (67%) severely ill patients had no change of menstrual cycle, respectively, while 21 (18%) mildly ill patients and 12 (21%) severely ill patients showed prolonged menstrual cycles. Menstrual cycles were shortened in 4 (3%) mildly ill patients and 1 (2%) severely ill patients, and 6 patients in each group had a cycle disorder. It was obvious that the menstrual cycle changes of COVID-19 patients tended to be prolonged, and further statistical analysis showed that there was no significant difference in any form of menstrual cycle change between the mild patients and severe patients (3D-F). When we followed-up the patients with menstrual changes by telephone two months after discharge, eight patients with a decreased menstrual volume had not returned to normal while two had improved symptoms. Except for a 44-year-old patient whose menstrual cycle had not yet normalized, the menstrual cycle of the other patients returned to their normal cycle. We also analyzed the menstrual changes of the 91 controls and compared with the COVID-19 patients from January to May, 2020. The results were shown in Figure S2 . Whether the menstrual volume or the menstrual cycles was changed more obviously in COVID-19 patients. Univariate logistic regression was performed to analyze the possible risk factors of menstrual cycle prolongation. Age, severity of illness, comorbidities, the presence of complications in other organs, and glucocorticoid treatment were included in analysis. Only the presence of complications was associated with menstrual cycle prolongation. The sex hormones levels and AMH levels in the early follicular stage in 91 COVID-19 patients and 91 controls are shown in Figure 4 . In total, the average levels of sex hormones, including FSH, LH, estradiol, progesterone, testosterone and AMH, were marginally higher in both mildly and severely ill patients than in the control group. However, no significant difference was found between COVID-19 patients and control or between mild and severe patients. Further subgroup analysis of sex hormones and AMH in patients with menstrual changes showed no significant differences in the average levels of all hormones in patients with either menstrual changes alone or periodic changes, or both ( Figure S1 ). As is well known, there are many forms of viruses affecting the female reproductive endocrine system. For example, menstrual disorders are prevalent in women with HBV or HCV infections, and reproductive dysfunction in the form of pregnancy loss and infertility have also been detected (Kurmanova, 2016 ). An earlier age of onset of menopause was found in women with HIV (Nanette, 2005) . Continuous infection by hantavirus has been confirmed in animal experiments to affect female fecundity (Kallio, et al., 2015) . However, no previous study has evaluated the impact of COVID-19 on the female sex hormone, menstruation and fertility. To our knowledge, this is the first study focusing on the clinical and laboratory findings, and especially the sex hormone, menstruation as well as ovarian reserve in women of child-bearing age infected with COVID-19. The findings of our study showed that severely ill patients had more comorbidities and complications and higher mortality than mildly ill patients. The higher PCT and cytokines levels in the severe group indicate more serious infection states and a cytokine storm in severe patients. By analyzing the menstrual changes of patients, we found that patients had a various extent of transient menstrual changes, mainly manifesting as longer menstrual cycles, prolonged cycles and decreased volume. A few patients also showed shortened or disordered menstrual cycles and increased volume which were rarely observed in the control group. Menstruation is regulated by the ovary and is easily disturbed by external factors such as infections, drug treatments, and other organ dysfunctions (Kala, et al., 2016 , Karagiannis, 2005 . To explain the menstrual changes, univariate logistic regression was performed on these possible factors. Consequently, the presence of systemic complications was found to be strongly correlated with menstrual changes. This suggested menstrual changes, which were often neglected by clinicians, were more likely to appear in patients with multisystem dysfunction. In addition, follow-up showed that 84% returned to a normal menstrual volume, and 99% of patients returned to their normal cycle within one to two months after discharge, suggesting that changes in menstruation caused by COVID-19 were most likely temporary changes and resolved in a short period. One 44-year-old patient indicated in the follow-up that she had stopped menstruating for four months after COVID-19 onset and had excluded pregnancy as a cause, but considering that she was within the perimenopausal period, we believe that the observation time of menstruation should be extended in her case. We further analyzed the sex hormone changes in 91 patients during the disease. Our data showed no statistically significant differences in all of the sex hormone levels between the COVID-19 patients and the controls. Subgroup analysis based on menstrual changes also indicated that there were no significant changes in sex hormone levels in either menstrual volume changes, simple cycle changes, or simultaneous volume and cycle changes. This result indicated that the ovarian endocrine system of most female COVID-19 patients was not seriously affected. However, some patients had abnormal changes in their sex hormone levels, such as inappropriately high levels of FSH and LH during the early follicular phase, which may indicate ovarian suppression in these patients. When placed under acute stress, ovarian function is usually suppressed to ensure normal operation of essential organs and anovulation has been reported in many acute diseases (Karagiannis, 2005) . Although we did not examine the levels of sex hormones in the early follicular phase again in the recovered patients, based on the fact that menstruation returned to normal in most patients after discharge, it is reasonable to assume that the changes in hormone levels were only temporary and transient. However, a direct effect of the virus could not be completely ruled out. To further explore the effects of SARS-CoV-2 infection on ovarian reserve, the patients were tested for AMH. AMH is secreted by small antral follicles and is an important indicator for evaluating ovarian reserve. It is not affected by the menstrual cycle, exogenous sex hormones or pregnancy (Iliodromiti, et al., 2015 , La Marca, et al., 2010 . The average AMH level of COVID-19 patients showed no difference compared with the controls. Considering the transient and reversible menstrual changes and that the estradiol and progesterone levels were not decreased in female COVID-19 patients, we assume that SARS-CoV-2 infection might have little impact on ovarian reserve. Certainly, we require additional clinical evidence and laboratory data to support our suspicion. This study also has some limitations. First, due to the retrospective and descriptive study design, some of the patients' menstrual histories were not recorded in the electronic medical record system. Thus, those patients were not included in the menstrual and sex hormone analysis. Second, only menstrual information was followed up after the patients' discharge. Sex hormone and AMH examinations were not performed after recovery. Finally, because there were no available autopsy or biopsy specimens of the ovary, we could not check whether SARS-CoV-2 is present in ovarian tissue and whether it could cause long-term damage. In conclusion, there was no evidence supporting SARS-CoV-2 causing substantial impairment of the fertility in female COVID-19 patients. Nevertheless, transient abnormal changes in menstruation were observed in some patients, along with hormone levels changes. For COVID-19 patients with menstrual abnormalities, home observations are recommended after excluding pregnancy, which can reduce the waste of medical resources and avoid hospital infections, especially in the current serious epidemic situation. We also suggest that the patients should undergo an examination of sex hormone levels and ovarian function before planning a pregnancy. The pattern of Middle East respiratory syndrome coronavirus in Saudi Arabia: a descriptive epidemiological analysis of data from the Saudi Ministry of Health Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study Clinical characteristics of 113 deceased patients with coronavirus disease 2019: retrospective study The novel angiotensin-converting enzyme (ACE) homolog, ACE2, is selectively expressed by adult Leydig cells of the testis China Medical Treatment Expert Group for, Covid. Clinical Characteristics of Coronavirus Disease 2019 in China China Medical Treatment Expert Group for C. Clinical Characteristics of Coronavirus Disease 2019 in China SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor Evidence that angiotensin-(1-7) is an intermediate of gonadotrophin-induced oocyte maturation in the rat preovulatory follicle Clinical features of patients infected with 2019 novel coronavirus in Wuhan Technical and performance characteristics of anti-Mullerian hormone and antral follicle count as biomarkers of ovarian response Role of cortisol and superoxide dismutase in psychological stress induced anovulation Age-related effects of chronic hantavirus infection on female host fecundity Pubertal abnormalities in adolescents with chronic disease Gonadal dysfunction in systemic diseases Do men have a higher case fatality rate of severe acute respiratory syndrome than women do? Anti-Mullerian hormone (AMH) as a predictive marker in assisted reproductive technology (ART) Effect of SARS-CoV-2 infection upon male gonadal function: A single center-based study HIV Infection, Drug Use, and Onset of Natural Menopause Specific ACE2 Expression in Small Intestinal Enterocytes may Cause Gastrointestinal Symptoms and Injury after 2019-nCoV Infection Cardiovascular Complications in Patients with COVID-19: Consequences of Viral Toxicities and Host Immune Response Dr Kezhen Li is Gynaecologist at Department of Gynecology and Obstetrics, Tongji Hospital, Tongji Medical College Key message: COVID-19 did not affect the average sex hormone levels and ovarian reserve of women of child-bearing age. However, part of COVID-19 patients exhibited menstrual volume decrease or cycle prolongation which might be the consequence of transient suppression of ovarian function that soon resumed after recovery This study was supported by the National Key Research and Development Program [2019YFC1005200, 2019YFC1005202], and the Hubei Province Health and Family Planning Scientific Research Project[WJ2019M127]. The funding organizations had no role in the design or conduct of the study; collection, management, analysis, or interpretation of the data; preparation, review, or approval of the manuscript; or the decision to submit the manuscript for publication. G.C., K.L., and H.L. contributed equally to this article. J.A. and L.C. were responsible for the study design, editing and revision. K.L., G.C., J.C., Q.L., and H.B. collected and analyzed the data. S.L. offered language help. H.H and C.W. were responsible for technical and material support. G.C. drafted the manuscript. We thank Yiduyun